Do you want to read an article? Please log in or register.
Use of statin for the primary prevention of cardiovascular outcomes in elderly patients: A propensity-matched cohort study
Cardiovascular Risk and Diseases
Related content
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Cardiovascular Disease Risk-Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circ Cardiovasc Qual Outcomes
Saeed A, Zhu J, Thoma F, Marroquin O, Aiyer A, Agarwala A, Virani SS, Gulati M, Lee JS, Reis S, Saba S, Ballantyne C, Mulukutla S
doi: 10.1161/CIRCOUTCOMES.120.007485
Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group
doi: 10.1161/CIRCULATIONAHA.
Cardiovascular Risk and Diseases
Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease: A Population-Based Retrospective Cohort Study
Circulation
Doumouras A, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride JÉ, Thabane L, Hong D, Yusuf S, Anvari M
doi: 10.1161/CIRCULATIONAHA.120.052386
Heart Failure
Association Between Use of Primary Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients with Heart Failure: A Prospective Propensity-Score Matched Analysis from the Swedish Heart Failure Registry
Circulation.
Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde CM, Braunschweig F, Savarese G
doi: 10.1161/CIRCULATIONAHA.119.043012.
Cardiovascular Risk and DiseasesAtrial FibrillationHeart FailureHypertensionMyocardial InfarctionThrombosis and Stroke
Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study
Lancet Diabetes Endocrinol.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Eur Heart J.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S
doi: 10.1093/eurheartj/ehx566.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Cardiovascular Risk and Diseases
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT
Circulation.
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
doi: 10.1161/CIRCULATIONAHA.
Thrombosis and StrokeTherapy and Intervention
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
Lancet Haematol.
Larsen TB, Skjøth F, Kjældgaard JN, Lip GYH, Nielsen PB, Søgaard M
doi: 10.1016/S2352-3026